Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DYNACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DYNACIN.
ACHROMYCIN vs DYNACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic